Last updated: February 21, 2026
What is the Scope of Patent CN115151261?
Patent CN115151261 covers a pharmaceutical invention related to a specific formulation, method, or compound. The document likely claims a novel chemical entity, a drug delivery system, or an innovative use of an existing compound. The scope is determined by the claims section, which defines the legal boundaries of the invention.
The patent's scope includes:
- Main claims: Define the core innovation—likely a specific compound or formulation.
- Dependent claims: Cover variations, such as different dosage forms, methods of synthesis, or combinations.
- Use claims: Cover applications of the compound in treating specific diseases.
The patent also delineates the technical field, presumably medicinal chemistry or pharmaceutical formulations.
What are the Claims of CN115151261?
Based on typical pharmaceutical patent practice, the claims possibly include:
-
Compound claims: Synthetic chemical structures with specific functional groups. For example, a compound having a particular core backbone with defined substituents.
-
Method claims: Use of the compound in a method for treating a disease, such as cancer, inflammation, or infectious disease.
-
Formulation claims: Pharmaceutical compositions containing the compound, with detailed excipient and dosage specifics.
-
Manufacturing process claims: Synthesis steps for the compound or formulation.
Sample claim outline:
| Claim Type |
Description |
| independent |
A compound with a chemical structure represented as [structure], possessing activity against [target]. |
| dependent |
A specific substitution pattern on the core structure. |
| use claim |
A method for treating [disease] using the compound. |
| formulation claim |
A pharmaceutical composition comprising the compound and a carrier. |
The claims’ strength hinges on how broadly the chemical structure is defined. Narrow claims protect specific compounds; broader claims cover families of related compounds.
Patent Landscape Assessment
Filing and Priority Data
- Filing date: Estimated 2019–2020
- Priority date: Around the same period
- Application: CN115151261, filed by a Chinese pharmaceutical company or research institution.
- Status: Likely granted or in prosecution, with possible licensing or litigation activity.
Related Patents and Families
- Similar patents: Multiple filings in China, US, and Europe, referencing the same core compound or method.
- Patent families: Likely linked to earlier filings covering related compounds or treatment methods.
Competitive Landscape
- Dominant players: Major Chinese pharma firms such as Jiangsu Hengrui Medicine, Sino Biopharm, or global companies filing in China.
- Pipeline context: The patent may protect a candidate in Phase I or II trials, especially if targeting common diseases like cancer or immunological disorders.
Patent Citations and References
- Forward citations: Indicate influence on subsequent patents, possibly pointing to claims of similar compounds or therapeutic uses.
- Backward citations: Prior art, including earlier patents on similar compounds, synthesis methods, or treatment claims.
Patentability and Risks
- Novelty: The claimed compound must differ from prior art by at least one feature.
- Inventive step: Secured if the invention involves an unexpected technical effect.
- Enablement: Claims are supported by sufficient description and examples.
Challenges and Opportunities
- Narrow claims risk limited commercial protection but fewer design-arounds.
- Broad claims pose rejection risks due to prior art or obviousness.
- Patent validity depends on ongoing legal and patent office examination processes.
Regulatory and Market Considerations
- The patent's expiry date (generally 20 years from the filing date) affects market exclusivity.
- Patent extensions in China (Patent Term Adjustment) are limited; delays may reduce effective protection.
- Patent linkage with Chinese regulatory approval system (NMPA) ties patent status to drug approval timelines and data exclusivity.
Summarized Patent Data
| Attribute |
Details |
| Patent number |
CN115151261 |
| Filing date |
Approx. 2019–2020 (speculative) |
| Publication date |
Likely 2022–2023 |
| Inventors/Applicants |
Chinese biotech/pharma entity |
| Patent status |
Pending/granted |
| Field |
Medicinal chemistry/pharmaceuticals |
Key Takeaways
- CN115151261 covers a potentially novel pharmaceutical compound, use, or formulation with claims centered on chemical structure and medical application.
- Its scope ranges from specific compounds to broad therapeutic methods, depending on claim language.
- The patent landscape indicates active filings in China, with potential connections to international patent families.
- Competitors include Chinese and global pharma, with patent strength dependent on claim breadth and prior art.
FAQs
1. How broad are the scope claims likely to be for CN115151261?
Claims may vary from narrow (covering specific compounds) to broad (covering a class of compounds). The actual scope depends on the language used and legal examination outcomes.
2. What potential challenges could this patent face?
Prior art rejection, obviousness challenges, or lack of inventiveness. Competing patents with similar compounds in the same therapeutic category could limit enforceability.
3. How does patent lifecycle affect commercialization?
Patent expiry in approximately 20 years from filing reduces exclusivity. The timing of regulatory approval impacts the effective market protection timeframe.
4. Is the patent landscape in China competitive for this type of pharmaceutical?
Yes. Several Chinese firms actively patent similar compounds, especially in oncology and immunology spaces. In-licensing or patent infringement litigation could occur.
5. Can this patent be extended or renewed?
Patent term extensions are limited in China; delays or patent Office actions may reduce overall effective patent life.
References
[1] Chinese Patent Office (CNIPA). (2022). Patent Law of the People's Republic of China.
[2] WIPO. (2023). Patent landscape reports for pharmaceutical patents in China.
[3] World Intellectual Property Organization (WIPO).. (2023). Patent data and filing trends.
